Senate bill targets drug patent abuses to cut medical costs

The Senate HELP Committee will vote on 17 June on a set of bills designed to lower medical costs. One of these, the Medication Affordability and Patent Integrity Act, aims to stop drug companies from exploiting the patent system. It introduces new disclosure and certification rules for patent applications. The bill seeks to align the FDA and USPTO by requiring both agencies to use the same factual basis. This change would prevent companies from securing patents they do not deserve. However, it may also slow down patent reviews, as examiners face a heavier workload.

Pharmaceutical firms have raised concerns about confidentiality. The proposal could force them to share sensitive, proprietary details with the USPTO. This would increase compliance tasks, legal reviews, and potential litigation for drugmakers.

Critics argue the bill could make the patent system less predictable. It may also expose patents to more challenges. Supporters of the current system note that applicants already follow strict disclosure rules, including a duty of candor and good faith. So far, there is no clear proof that companies are hiding key information from examiners. The bill could reshape how pharmaceutical patents are reviewed and approved. It may add transparency but also increase administrative burdens and legal risks. The Senate committee’s decision will determine whether these changes move forward.